Spyre Therapeutics (SYRE) Competitors

Spyre Therapeutics logo
$101.46 +7.65 (+8.15%)
Closing price 04:00 PM Eastern
Extended Trading
$101.43 -0.03 (-0.03%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SYRE vs. BIIB, GMAB, ROIV, INSM, and UTHR

Should you buy Spyre Therapeutics stock or one of its competitors? Spyre Therapeutics's main competitors and comparable companies include Biogen (BIIB), Genmab A/S (GMAB), Roivant Sciences (ROIV), Insmed (INSM), and United Therapeutics (UTHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Spyre Therapeutics compare to Biogen?

Spyre Therapeutics (NASDAQ:SYRE) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spyre Therapeutics currently has a consensus target price of $110.53, indicating a potential upside of 17.83%. Biogen has a consensus target price of $254.41, indicating a potential upside of 1.44%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Spyre Therapeutics is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67

Spyre Therapeutics has a beta of 3.24, meaning that its share price is 224% more volatile than the broader market. Comparatively, Biogen has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Biogen has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre Therapeutics$890K10,010.26-$155.20M-$2.74N/A
Biogen$9.89B3.75$1.29B$2.34107.18

In the previous week, Biogen had 35 more articles in the media than Spyre Therapeutics. MarketBeat recorded 36 mentions for Biogen and 1 mentions for Spyre Therapeutics. Biogen's average media sentiment score of 1.14 beat Spyre Therapeutics' score of 0.60 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
18 Very Positive mention(s)
4 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has a net margin of 3.37% compared to Spyre Therapeutics' net margin of 0.00%. Biogen's return on equity of 9.38% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -35.97% -27.67%
Biogen 3.37%9.38%5.69%

Summary

Biogen beats Spyre Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Genmab A/S?

Spyre Therapeutics (NASDAQ:SYRE) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Spyre Therapeutics has a beta of 3.24, meaning that its share price is 224% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genmab A/S has a net margin of 16.97% compared to Spyre Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 13.67% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -35.97% -27.67%
Genmab A/S 16.97%13.67%6.42%

Spyre Therapeutics presently has a consensus price target of $110.53, indicating a potential upside of 17.83%. Genmab A/S has a consensus price target of $53.50, indicating a potential upside of 2.96%. Given Spyre Therapeutics' higher possible upside, research analysts clearly believe Spyre Therapeutics is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00

Genmab A/S has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre Therapeutics$890K10,010.26-$155.20M-$2.74N/A
Genmab A/S$3.72B8.72$963M$1.1744.41

In the previous week, Genmab A/S had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 7 mentions for Genmab A/S and 1 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.60 beat Genmab A/S's score of -0.18 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Genmab A/S beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Roivant Sciences?

Spyre Therapeutics (NASDAQ:SYRE) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Spyre Therapeutics presently has a consensus target price of $110.53, suggesting a potential upside of 17.83%. Roivant Sciences has a consensus target price of $46.82, suggesting a potential upside of 20.95%. Given Roivant Sciences' higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Spyre Therapeutics has higher earnings, but lower revenue than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre Therapeutics$890K10,010.26-$155.20M-$2.74N/A
Roivant Sciences$8.26M3,395.61-$299.77M-$0.63N/A

In the previous week, Roivant Sciences had 14 more articles in the media than Spyre Therapeutics. MarketBeat recorded 15 mentions for Roivant Sciences and 1 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.60 beat Roivant Sciences' score of 0.58 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Roivant Sciences
6 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Spyre Therapeutics has a beta of 3.24, indicating that its share price is 224% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -838.21%. Roivant Sciences' return on equity of -22.03% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -35.97% -27.67%
Roivant Sciences -838.21%-22.03%-20.55%

Summary

Spyre Therapeutics beats Roivant Sciences on 10 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Insmed?

Spyre Therapeutics (NASDAQ:SYRE) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Insmed had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 7 mentions for Insmed and 1 mentions for Spyre Therapeutics. Insmed's average media sentiment score of 0.86 beat Spyre Therapeutics' score of 0.60 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Spyre Therapeutics presently has a consensus target price of $110.53, suggesting a potential upside of 17.83%. Insmed has a consensus target price of $196.52, suggesting a potential upside of 61.27%. Given Insmed's higher possible upside, analysts clearly believe Insmed is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92

Spyre Therapeutics has a beta of 3.24, meaning that its stock price is 224% more volatile than the broader market. Comparatively, Insmed has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -39.85%. Spyre Therapeutics' return on equity of -35.97% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -35.97% -27.67%
Insmed -39.85%-96.38%-32.55%

Spyre Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre Therapeutics$890K10,010.26-$155.20M-$2.74N/A
Insmed$606.42M44.08-$1.28B-$2.82N/A

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Spyre Therapeutics beats Insmed on 11 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, United Therapeutics had 21 more articles in the media than Spyre Therapeutics. MarketBeat recorded 22 mentions for United Therapeutics and 1 mentions for Spyre Therapeutics. United Therapeutics' average media sentiment score of 0.83 beat Spyre Therapeutics' score of 0.60 indicating that United Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
United Therapeutics
8 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Spyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

United Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.24, meaning that its share price is 224% more volatile than the broader market.

United Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$3.18B7.82$1.33B$26.5022.04
Spyre Therapeutics$890K10,010.26-$155.20M-$2.74N/A

United Therapeutics has a net margin of 38.61% compared to Spyre Therapeutics' net margin of 0.00%. United Therapeutics' return on equity of 19.18% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
United Therapeutics38.61% 19.18% 17.07%
Spyre Therapeutics N/A -35.97%-27.67%

United Therapeutics currently has a consensus target price of $676.40, suggesting a potential upside of 15.80%. Spyre Therapeutics has a consensus target price of $110.53, suggesting a potential upside of 17.83%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

United Therapeutics beats Spyre Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Spyre Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYRE vs. The Competition

MetricSpyre TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9.64B$3.97B$7.60B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio-37.0324.6233.5830.13
Price / Sales10,826.5815.438.255.59
Price / CashN/A22.9521.0121.90
Price / Book10.654.164.443.72
Net Income-$155.20M-$24.10M$3.50B$393.88M
7 Day Performance-5.02%-8.44%-6.53%-6.07%
1 Month Performance26.98%-6.54%-4.93%-7.38%
1 Year Performance321.00%-6.71%-1.73%-7.48%

Spyre Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYRE
Spyre Therapeutics
1.8695 of 5 stars
$101.46
+8.2%
$110.53
+8.9%
+285.1%$9.64B$890KN/A130
BIIB
Biogen
2.9767 of 5 stars
$253.25
-0.6%
$254.41
+0.5%
+52.3%$37.44B$9.89B108.237,500
GMAB
Genmab A/S
2.6332 of 5 stars
$54.07
-3.1%
$53.61
-0.8%
+70.8%$33.74B$3.72B46.213,029
ROIV
Roivant Sciences
2.4733 of 5 stars
$41.19
+1.3%
$46.64
+13.2%
+88.3%$29.75B$8.26MN/A721
INSM
Insmed
3.2303 of 5 stars
$119.49
+2.9%
$196.52
+64.5%
-38.3%$26.21B$606.42MN/A1,664

Related Companies and Tools


This page (NASDAQ:SYRE) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners